A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC [0.03%]
一个新的CA19-9截断值可确定Lewis抗原状态并细化胰腺导管腺癌的预后分层
Chia-Ming Yeh,Chih-Chuan Yu,An-Fu Lee et al.
Chia-Ming Yeh et al.
Purpose: Carbohydrate antigen 19-9 (CA19-9) has limited utility in the ∼10% of patients with pancreatic ductal adenocarcinoma (PDAC) who are Lewis-negative CA19-9 "nonproducers" (FUT3-null). This study aims to define the...
Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trial [0.03%]
CAPItello-291三期试验的PTEN缺失免疫组化探索性分析
Komal Jhaveri,Hope S Rugo,Javier Cortés et al.
Komal Jhaveri et al.
Purpose: The PI3K/AKT pathway is frequently activated in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, with loss of phosphatase and tensin homolog (PTEN) a...
Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma [0.03%]
预测黑色素瘤过继性细胞治疗效果的CD8+t细胞表型和功能特征
Joachim S Granhøj,Sigrid M H Mannering,Kasper Madsen et al.
Joachim S Granhøj et al.
Purpose: Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is a highly personalized cancer immunotherapy. In the randomized Phase III clinical trial (TIL-NKI/CCIT), TIL therapy significantly improved progres...
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco [0.03%]
无驱动基因改变且从未使用烟草的肺腺癌患者接受PD-(L)1抑制剂治疗的临床疗效及预测因素分析
Eleonora Gariazzo,Arielle Elkrief,Kyle Concannon et al.
Eleonora Gariazzo et al.
Purpose: Predictive biomarkers of response to immune checkpoint inhibitors (ICI) remain poorly defined in patients with non-small cell lung cancer (NSCLC) without a history of tobacco use and lacking actionable genomic al...
Dose Escalation With Intensity-Modulated Proton Therapy for Patients with High-Risk Meningiomas - Results From a Phase 1 Trial [0.03%]
调强质子治疗高危脑膜瘤的剂量爬坡试验——一项I期临床试验的结果分析
Felix Ehret,Nora K Horick,Beow Y Yeap et al.
Felix Ehret et al.
Background: Outcomes for grade 2 and 3 meningiomas are poor. A few studies suggest a benefit from radiation therapy dose escalation. This trial evaluates the safety and efficacy of dose escalation with intensity-modulated...
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial [0.03%]
解析透明细胞肾细胞癌的肿瘤微环境，以确定抗PD-1治疗结局的生物标志物：HCRN GU16-260试验分析
Nourhan El Ahmar,Morgan A Paul,Berkay Simsek et al.
Nourhan El Ahmar et al.
Purpose: We investigated components of the immune tumor microenvironment as determinants of clinical outcome to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with frontline...
Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid Tumors [0.03%]
脂质纳米颗粒包封的编码人类OX40L、IL-23和IL-36γ的mRNA-2752联合度伐利尤单抗在晚期实体瘤患者中诱导肿瘤微环境免疫刺激作用：一项1期临床试验
Randy F Sweis,Georgina V Long,Adil Daud et al.
Randy F Sweis et al.
Purpose: mRNA-2752, a lipid nanoparticle (LNP)‒encapsulated, mRNA-based therapeutic encoding OX40L, IL-36γ, and IL-23, has demonstrated modulation of the tumor microenvironment (TME) and antitumor efficacy in combinatio...
Glycoprotein mucin 13 expression as a theranostic target in colorectal cancer [0.03%]
糖蛋白黏蛋白13在结直肠癌中作为诊疗靶标的表达状况研究
Aiko Yamaguchi,Ryan P Coll,Jianbo Wang et al.
Aiko Yamaguchi et al.
Purpose: The high mortality associated with metastatic colorectal cancer (mCRC) illuminates an unmet need for innovative therapeutic modalities. Radiopharmaceutical therapy (RPT) offers a potent, molecular scale approach ...
Incidence of B cell malignancies in patients with lung cancer receiving PD-1 blockade therapy [0.03%]
PD-1阻断治疗肺癌患者中B细胞恶性肿瘤的发生率
Toshifumi Ninomiya,Caiyang Fang,Hirofumi Hamano et al.
Toshifumi Ninomiya et al.
Purpose: Many patients with various cancers have received immune checkpoint inhibitors (ICIs) worldwide since their approval, and novel unexpected complications from their long-term use are apparent. We identified some ca...
Comprehensive Genomic and Transcriptomic Characterization of MTAP Loss Across Advanced Solid Tumors [0.03%]
来自高级别实体瘤的MTAP丢失的全基因组及转录组特征分析
Kyosuke Seguchi,Takao Fujisawa,Sadakatsu Ikeda et al.
Kyosuke Seguchi et al.
Purpose: Methylthioadenosine phosphorylase (MTAP) is a tumor suppressor gene, with loss of MTAP occurring in approximately 15% of solid tumors; however, its molecular and clinicopathological significance remains incomplet...